Grant received in 2020
DCCC has funded 126,000 DKKK to the preparation of this national and multidisciplinary investigator-initiated study.
This preparatory effort will lay out, how large a proportion of Danish patients with Gastric- and Esophageal cancer, who have HER2-molecules on cancer cells. HER2 causes overstimulation and uncontrollable division of cells. A treatment for HER2 exits, but is not tested on this type of cancer – which the DCCC funding will contribute to investigate. The preliminary work is done in collaboration with Danish EsophagoGastric Cancer Group (DEGC) and with participation from all four treatment facilities in Denmark.
Project Stakeholders
All departments of oncology treating ESCC in Denmark will participate actively in the development of the protocol and accrue
patients in the clincial trial ensuring nationwide enrollment.
University Hospital Rigshospitalet:
- Kristian Egebjerg, Department of Oncology
- Jon Kroll Bjerregaard, Department of Oncology
- Lene Bæksgaard Jensen, Department of Oncology
- Rajendra Singh Garbyal, Department of Pathology
- Jane Preuss Hasselby, Department of Pathology
Aarhus University Hospital:
- Marianne Nordsmark, Department of Oncology
- Stephen Hamilton Dutoit, Department of Pathology
Odense University Hospital:
- Eva Holtved, Department of Oncology,
- Tine Di Caterino, Department of Pathology
Aalborg University Hospital:
- Morten Ladekarl, Department of Oncology. Primary contact, mail: mms@rh.regionh.dk
- Mikkel Eld, Department of Pathology
News
DCCC Strengthens Danish Cancer Research With 1.7 Million DKK, November 27, 2020